Sun Pharma.Inds.
Sun Pharmaceutical Industries Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹14,478Cr
- +8.9% YoY
- Net profit
- ₹3,125Cr
- +2.9% YoY
- Margin
- 31%
- +1 pp YoY
Guidance rank: #86 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Global Innovative Medicines sales up 16.4% in Q2 FY26; strong growth expected to continue. Sun Pharma expects normalized tax rate around 25% for the full year, up from prior lower rates due to expiring tax benefits.
From Sun Pharma.Inds.'s Q2 FY26 earnings-call transcript · updated 24 Aug 2026.
Revenue & Sales Performance
- Global Innovative Medicines sales up 16.4% in Q2 FY26; strong growth expected to continue.
- U.S. Innovative Medicine sales have surpassed generics for the first time, indicating growth focus.
- India formulation sales grew 11% in Q2, outpacing Indian Pharmaceutical Market (IPM) growth mainly driven by volume and new product launches.
- Specialty products like ILUMYA expected to continue prescription growth due to expanding markets.
- Targeted treatments like Leqselvi market expected to grow with increasing prescriber confidence and payer coverage.
- GLP-1 market described as very exciting with expected growth; Sun Pharma aims to participate actively.
2 more points from Sun Pharma.Inds.'s call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Sun Pharma.Inds. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Sun Pharma undertook short-term borrowings linked to the recent acquisition, expected to normalize in coming quarters (Page 17).
- Investment in subsidiaries mainly relates to the Checkpoint acquisition (Page 12).
- Increase in intangible assets primarily due to Checkpoint acquisition (~$471 million), Leqselvi (~$300 million), and milestone payments like ODOMZO (Page 6).
2 more points from Sun Pharma.Inds.'s call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sun Pharma.Inds. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Sun Pharma.Inds. — Quarterly revenue & net profit
Sun Pharma.Inds. Q2 FY26 results — key figures
| ₹ Cr | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 14,478 | 13,291 | +8.9% | 13,851 | +4.5% |
| Operating profit (EBITDA) | 4,527 | 3,939 | +14.9% | 4,302 | +5.2% |
| Operating margin | 31% | 30% | +1 pp | 31% | 0 pp |
| Profit before tax | 4,168 | 3,598 | +15.8% | 3,173 | +31.4% |
| Net profit (PAT) | 3,125 | 3,037 | +2.9% | 2,293 | +36.3% |
| EPS (₹) | 13.00 | 12.67 | +2.6% | 9.50 | +36.8% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹16.2K Cr, net profit ₹2.0K Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sun Pharmaceutical Industries's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Sun Pharma.Inds. and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sun Pharma.Inds. Q2 FY26 results?
Global Innovative Medicines sales up 16.4% in Q2 FY26; strong growth expected to continue. Sun Pharma expects normalized tax rate around 25% for the full year, up from prior lower rates due to expiring tax benefits.
What is Sun Pharma.Inds. share price analysis?
Sun Pharma.Inds. currently shows a neutral. The stock trades at a P/E of 36.1 with a market cap of ₹456,449 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sun Pharma.Inds. planning capital expenditure?
Sun Pharma undertook short-term borrowings linked to the recent acquisition, expected to normalize in coming quarters (Page 17). - Investment in subsidiaries mainly relates to the Checkpoint acquisition (Page 12). - Increase in intangible assets primarily due to Checkpoint acquisition (~$471 million), Leqselvi (~$300 million), and milestone payments like ODOMZO (Page 6). - Specialty launches (Leqselvi and Unloxcyt) are supported by incremental spend of around $100 million in the fiscal year, with expense ramp-up expected in Q3 and Q4 (Page 6). - Manufacturing footprint in the U.S.
Keep Sun Pharma.Inds. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.